medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2018, Number 02

<< Back Next >>

Ginecol Obstet Mex 2018; 86 (02)

Use of Floseal® hemostatic matrix in the management of obstetric hemorrhage: A follow-up and costs related to treatment

Martínez-Gaytán V, Torcida-González ME, Félix-Zamudio LL, Álvarez-Chávez LD, Barrientos-Navarro MC, Briones-Lara E

Language: Spanish
References: 32
Page: 127-136
PDF size: 345.40 Kb.


ABSTRACT

Objective: To evaluate the clinical outcomes and direct costs related to treatment of placenta previa with Floseal® hemostatic matrix as part of the treatment of obstetric hemorrhage in comparison with conventional management only.
Methods: Clinical records of patients with hemorrhagic hemorrhage, with more than 20 weeks of pregnancy and placenta previa were reviewed, all patients were adults and treated within September and November of 2012 in the “Unidad Médica de Alta Especialidad 23” of the Mexican Institute of Social Security, Monterrey, México. Costs where estimated using the Diario Oficial de la Federación 2013) and a resampling was performed. Clinical and costs outcomes where compared with parametric and non-parametric tests.
Results: 29 clinical records (15: Adjuvant Floseal®, 14: conventional treatment only). Floseal® group resulted in less re-interventions (0% vs 57.1%, p 0.0010), days of hospital stay [2(2-4) vs 6(4-11), p 0.0048] and days in the intensive care unit (2.4 ± 1.5 vs 4.5 ± 2.1, p 0.0048). Average cost by resampling was $109,172.00 [CI95% (80,153.10-139,073.71 mexican pesos)] for Floseal® vs 224,289.00 mexican pesos [IC95% (181,881.48-269,061.23)] for conventional treatment at the expense greater number of pieces of Tisseel®, cryoprecipitate, crystalloids and surgical removal of compresses.
Conclusions: The adjuvant use of Floseal® was associated with fewer re-interventions, days of hospital stay and intensive care. Lower average and total costs associated with treatment were also estimated. Future long-term analyzes and larger sample sizes are necessary to corroborate these results in the Mexican population.


REFERENCES

  1. Van de Velde M, Diez C, Varon AJ. Obstetric hemorrhage. Curr Opin Anesthesiol. 2015 Apr;28(2):186-190.

  2. Mercier FJ, Van de Velde M. Major obstetric hemorrhage. Anesthesiol Clin. 2008 Mar;26(1):53-66, vi.

  3. Aguli Ruíz-Rosas R, Cruz-Cruz P del R. Causas de mortalidad materna en el Instituto Mexicano del Seguro Social, periodo 2009-2012. Rev Médica Inst Mex Seguro Soc [Internet]. 2014 [cited 2017 Sep 18];52(4). Available from: http:// www.redalyc.org/resumen.oa?id=457745483010

  4. Zero Maternal Deaths. Zero Maternal Deaths from Hemorrhage [Internet]. [cited 2017 Sep 18]. Available from: http://www.paho.org/cero-muertes-maternashemorragia/? lang=en

  5. Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 2006 Apr;107(4):927-41.

  6. Crane JM, Van den Hof MC, Dodds L, Armson BA, Liston R. Maternal complications with placenta previa. Am J Perinatol. 2000;17(2):101-5.

  7. Lewis G. Why Mothers Die 2000-2002: The Sixth Report of the Confidential Enquiries Into Maternal Deaths in the United Kingdom. RCOG; 2004;15.

  8. Dogba M, Fournier P. Human resources and the quality of emergency obstetric care in developing countries: a systematic review of the literature. Hum Resour Health. 2009 Dec 1;7(1):7.

  9. FLOSEAL Hemostatic Matrix/Stops Bleeding Fast [Internet]. [cited 2017 Sep 23]. Disponible en: http://www.floseal. com/us/

  10. Echave M, Oyagüez I, Casado MA. Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review. BMC Surg [Internet]. 2014 Dec 20;14. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4289565/

  11. Moriarty KT, Premila S, Bulmer PJ. Use of Floseal® haemostatic gel in massive obstetric haemorrhage: a case report. BJOG Int J Obstet Gynaecol. 2008 May;115(6):793-5.

  12. Lai Wa LAw, Chung Ming Chor, Tak Yeung Leung. Use of Hemostatic Gel in Pospartum Hemorrhage Due to Placenta Previa. Obstetrics & Gynecology. 2010 Aug;116.

  13. Lemmer R, Albrech M, Bauer G. Use of Floseal® hemostatic matrix in a patient with severe postpartum hemorrhage. J Obstet Gynaecol Res. 2012 Feb;38(2):435-7.

  14. Floseal® and Hemostatic Matrix | Application. Instructions for Use [Internet]. [cited 2017 Nov 27]. Available from: http://www.floseal.com/int/instructions-for-use.htmL

  15. IMSS. Guía de práctica clínica. Diagnóstico y tratamiento de la hemorragia obstétrica en la segunda mitad del embarazo y puerperio inmediato [Internet]. Mexico; disponible en: http:// www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/ 162_GPC_HEMORRAGIA_OBSTETRICA/Imss_162RR.pdf

  16. College Station, TX:StataCorp LLC. Stata Statistical Software: Release 15.

  17. Diario Oficial de la Federación [Internet]. [citado el 24 de diciembre de 2017]. Disponible en: http://www.dof.gob.mx/

  18. Efron B. Bootstrap Methods: Another Look at the Jackknife. Ann Stat. 1979 Jan;7(1):1-26.

  19. Efron B. Better Bootstrap Confidence Intervals. J Am Stat Assoc. 1987 Mar 1;82(397):171-85.

  20. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997 Aug;6(4):327-40.

  21. Campbell DE. Incentives: motivation and the economics of information. 2nd ed. Cambridge [England] ; New York: Cambridge University Press; 2006. xii + 591.

  22. Leong T-Y. Monte Carlo Spreadsheet Simulation Using Resampling. Inf Trans Educ. 2007 May;7(3):188-200.

  23. Rochowicz J. Bootstrapping Analysis, Inferential Statistics and EXCEL. Spreadsheets Educ EJSiE [Internet]. 2010 Jun 21;4(3). Disponible en: http://epublications.bond.edu.au/ ejsie/vol4/iss3/4

  24. Campbell MK. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM. 1999 Mar 1;92(3):177-82.

  25. Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of Statistical Methods for Analysing Healthcare Resources and Costs. Health Econ. 2011 Aug;20(8):897-916.

  26. Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, et al. Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery. Obstet Gynecol. 2014 Sep;124(3):589-95.

  27. Byford S, Palmer S. Common Errors and Controversies in Pharmacoeconomic Analyses. PharmacoEconomics. 1998 Jun 1;13(6):659-66.

  28. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000 May 15;19(9):1141-64.

  29. Rodríguez Barrios JM. Papel de los modelos en la evaluaciones económicas en el campo sanitario. Farm Hosp Madr. 2004;28(4):231-42.

  30. Rubio-Terrés C, Cobo E, Antonio Sacristán J, Prieto L, del Llano J, Badia X. Análisis de la incertidumbre en las evaluaciones económicas de intervenciones sanitarias. Med Clínica. 2004 Jan;122(17):668-74.

  31. Giglio N, Caruso M, Castellano V, Choque L, Sandoval S, Micone P, et al. Costos de hospitalización por diarrea en niños durante el período de circulación de rotavirus en el Noroeste Argentino. Arch Argent Pediatr [Internet]. 2017 Dec 1 [cited 2017 Dec 1];115(6). Available from: http:// www.sap.org.ar/docs/publicaciones/archivosarg/2017/ v115n6a03.pdf

  32. Maes IHL, Cima RFF, Vlaeyen JW, Anteunis LJC, Joore MA. Tinnitus: a cost study. Ear Hear. 2013 Aug;34(4):508-14. systematic review. BMC Surg [Internet]. 2014 Dec 20;14.




2020     |     www.medigraphic.com